Reply to D. Vordermark and T. Pelz and R. Mazzola et al. by van Nimwegen, F, Cutter, D, Schaapveld, M, Darby, S, Aleman, B, van Leeuwen, F

Long-term risk of ischemic heart disease following Hodgkin lymphoma treatment by Van Nimwegen, F, Schaapveld, M, Krol, A, Janus, C, Cutter, D, Darby, S, Aleman, B, Van Leeuwen, F

Risk of valvular heart disease after treatment for Hodgkin lymphoma by Cutter, D, Schaapveld, M, Darby, S, Hauptmann, M, van Nimwegen, F, Krol, A, Janus, C, van Leeuwen, F, Aleman, B

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines by van Nimwegen, F, Ntentas, G, Darby, S, Schaapveld, M, Hauptmann, M, Lugtenburg, P, Janus, C, Daniels, L, van Leeuwen, F, Cutter, D, Aleman, B

Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma by van Nimwegen, F, Schaapveld, M, Cutter, D, Janus, C, Krol, A, Hauptmann, M, Kooijman, K, Roesink, J, van der Maazen, R, Darby, S, Aleman, B, van Leeuwen, F